Ships within 24 hours on business days · +10% with Bank Pay

MOTS-c Liquid Spray

Shop

MOTS-c Liquid Spray · Research brief

Humanin vs MOTS-c: How They Compare in Research

60 WORDS

Short answer

The short answer on humanin vs MOTS-c is that both peptides are encoded inside mitochondrial DNA rather than nuclear DNA, but they are read from different regions of the mitochondrial genome and act through different mechanism classes. Humanin is a 24-amino-acid peptide whose open reading frame sits inside the 16S rRNA gene, and the literature describes it primarily as a…

The short answer on humanin vs MOTS-c is that both peptides are encoded inside mitochondrial DNA rather than nuclear DNA, but they are read from different regions of the mitochondrial genome and act through different mechanism classes. Humanin is a 24-amino-acid peptide whose open reading frame sits inside the 16S rRNA gene, and the literature describes it primarily as a cytoprotective, anti-apoptotic signal acting at cell-surface receptor complexes and on the Bcl-2 family protein Bax. MOTS-c is a 16-amino-acid peptide encoded within the 12S rRNA gene, and research describes it primarily as a metabolic regulator that influences the folate one-carbon cycle and AMP-activated protein kinase signalling. SS-31, also called elamipretide, belongs to a third category entirely: it is a synthetic aromatic-cationic tetrapeptide designed to concentrate at the inner mitochondrial membrane and bind cardiolipin, not a product of the mitochondrial genome at all. This page compares the three across origin, mechanism, published models and research applications.

What is the core difference in humanin vs MOTS-c?

The core difference is mechanism class: humanin is studied as a survival and stress-protection signal, while MOTS-c is studied as a metabolic and exercise-mimetic signal. Both belong to the family now usually called mitochondrial-derived peptides, small polypeptides translated from short open reading frames hidden inside the mitochondrial genome, and both circulate in blood, which means both are treated in the literature as candidate signalling molecules rather than purely intracellular structural proteins.

From that shared starting point the two diverge. The founding humanin paper, A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta, published in Proceedings of the National Academy of Sciences in 2001, identified the peptide in a screen for factors that kept neuronal cells alive under insults linked to familial Alzheimer's disease genes (PMID 11371646). The framing from day one was cell survival. MOTS-c entered the literature a decade and a half later through The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance, published in Cell Metabolism in 2015, which described effects on glucose handling and body composition in rodent models of diet-induced obesity (PMID 25738459). The framing there was metabolic regulation.

Those two framings still define how the peptides are used in laboratory work. Groups asking about apoptosis, ischaemic stress, retinal or neuronal protection and chaperone-like activity tend to reach for humanin. Groups asking about insulin sensitivity, skeletal muscle energetics, glucose flux and exercise biology tend to reach for MOTS-c. The two are not interchangeable reagents, and studies that compare them directly in the same model remain relatively uncommon.

Where in the mitochondrial genome does each peptide come from?

Humanin and MOTS-c come from different ribosomal RNA genes inside the circular mitochondrial chromosome, which is one of the clearest structural distinctions between them. The human mitochondrial genome is small, roughly sixteen and a half kilobases, and was long assumed to encode only thirteen proteins of the electron transport chain plus the transfer and ribosomal RNAs needed to make them. The discovery of short open reading frames inside the rRNA genes changed that picture.

The humanin open reading frame lies within the 16S rRNA gene. Two forms appear in the literature: a 24-amino-acid peptide produced when the sequence is read by cytoplasmic ribosomes using the standard genetic code, and a 21-amino-acid peptide produced when the sequence is read inside the mitochondrion using the mitochondrial code. Much of the published work uses synthetic humanin or the substituted analogue often written as HNG, in which a serine at position 14 is replaced by glycine, a change that research reports makes the peptide markedly more potent in cytoprotection assays. Nuclear sequences with strong similarity to the humanin reading frame also exist, and this has complicated attempts to pin down exactly where circulating humanin is produced.

The MOTS-c open reading frame sits inside the 12S rRNA gene and encodes 16 amino acids. The 2015 Cell Metabolism report that introduced the peptide named it for its apparent action on the mitochondrial open reading frame of the 12S rRNA type-c (PMID 25738459). Because MOTS-c is shorter and chemically simpler than humanin, it is generally more straightforward to synthesise and handle, which partly explains why it has accumulated a broad experimental literature in a short period. Both peptides are catalogued alongside other mitochondrial-derived peptides such as the small humanin-like peptides, described in Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers, published in Aging in 2016 (PMID 27070352).

How does humanin work at the molecular level?

Humanin is described in the literature as acting through two broad routes: an extracellular route through receptor complexes at the cell surface, and an intracellular route through direct interaction with pro-apoptotic Bcl-2 family proteins. Neither route is fully mapped, and the balance between them likely depends on cell type and on whether the peptide is applied outside the cell or expressed inside it.

The intracellular route is the better characterised of the two. Humanin peptide suppresses apoptosis by interfering with Bax activation, published in Nature in 2003, reported that humanin binds Bax and prevents its translocation from the cytosol to mitochondria, a step normally required for mitochondrial outer membrane permeabilisation and the release of cytochrome c (PMID 12732850). By interrupting that step, humanin shifts cells away from the intrinsic apoptotic programme under stress. Later work in the field extended the same logic to other BH3-domain proteins, and the general description in reviews is that humanin acts as a brake on mitochondria-dependent cell death rather than as a growth signal.

The extracellular route involves a trimeric receptor complex that includes gp130 together with partner chains, and signalling downstream through STAT3 and ERK pathways. This receptor model helps explain why humanin applied to culture medium can protect cells that never express the peptide themselves, and why circulating concentrations are of interest as a systemic signal. Reviews such as Mitochondrially derived peptides as novel regulators of metabolism, published in The Journal of Physiology in 2017, place humanin in a retrograde signalling framework, in which mitochondria communicate their state outward to the rest of the cell and to distant tissues (PMID 28574175).

A third strand of humanin research concerns insulin action. Humanin: a novel central regulator of peripheral insulin action, published in PLoS One in 2009, reported that humanin influences glucose handling through central nervous system signalling in rodents rather than solely through direct peripheral effects (PMID 19623253). That overlap with metabolic biology is one of the few places where the humanin and MOTS-c literatures converge.

How does MOTS-c work at the molecular level?

MOTS-c is described primarily as a regulator of cellular fuel sensing, acting through the folate one-carbon cycle and the AMP-activated protein kinase pathway. The 2015 Cell Metabolism report linked MOTS-c to inhibition of the folate cycle, which in turn alters levels of the purine intermediate AICAR, a known endogenous activator of AMPK (PMID 25738459). Activating AMPK pushes cells toward catabolic, energy-generating programmes and away from anabolic storage, which is the mechanistic logic behind describing MOTS-c as an exercise-mimetic signal.

Research also describes MOTS-c moving into the nucleus under metabolic stress, where it has been reported to associate with stress-responsive transcription factors and influence antioxidant and adaptive gene expression. If that picture holds, MOTS-c would be unusual: a peptide encoded by the mitochondrial genome that physically relocates to the nuclear genome to coordinate a stress response. The field treats this as an attractive but still developing model, and the details of how the peptide crosses compartments are not settled.

In skeletal muscle, MOTS-c is studied as a modulator of glucose uptake and mitochondrial capacity. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis, published in Nature Communications in 2021, reported that the peptide rises with exercise in skeletal muscle and in circulation and that older animals in the study showed differences in physical performance measures associated with the peptide (PMID 33473109). That paper is the main reference point for groups interested in MOTS-c as a readout of exercise biology rather than as an intervention.

For laboratories working with the compound itself, Real Peptides lists MOTS-c as a catalog research compound, with the lyophilised MOTS-c peptide and a MOTS-c liquid spray presentation both intended for laboratory research use only.

How does humanin vs SS 31 differ in origin and design?

The difference in humanin vs SS 31 is categorical rather than incremental: humanin is an endogenous peptide written into mitochondrial DNA, while SS-31 is a synthetic tetrapeptide designed in a medicinal chemistry programme to accumulate inside mitochondria. They share a research field, not a biological family.

SS-31 belongs to the Szeto-Schiller series of aromatic-cationic peptides. The design principle is an alternating pattern of aromatic and basic residues that gives the molecule cell permeability without requiring a transporter, together with a net positive charge that drives accumulation at the inner mitochondrial membrane. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury, published in the Journal of Biological Chemistry in 2004, described this class and its behaviour in isolated mitochondria and cell models (PMID 15178689).

The mechanism later attributed to SS-31 is selective interaction with cardiolipin, the signature phospholipid of the inner mitochondrial membrane. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin, published in the Journal of the American Society of Nephrology in 2013, reported that the peptide associates with cardiolipin and influences the interaction between cardiolipin and cytochrome c, which bears on both electron transport efficiency and peroxidase activity that can generate reactive species (PMID 23813215). A companion account, First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics, published in the British Journal of Pharmacology in 2014, framed the compound as a membrane-structure stabiliser rather than a conventional free radical scavenger (PMID 24117165).

So the contrast is clean. Humanin signals; SS-31 structures. Humanin engages receptors and protein-protein interactions to change a cell's survival decision. SS-31 sits in a membrane and changes how efficiently that membrane's protein complexes work. Real Peptides lists SS-31 as a catalog research compound for laboratory use.

How do humanin, MOTS-c and SS-31 compare side by side?

The clearest way to hold the three apart is a direct comparison of origin, mechanism class and typical research application.

Attribute Humanin MOTS-c SS-31 (elamipretide)
Origin Encoded in the 16S rRNA region of mitochondrial DNA Encoded in the 12S rRNA region of mitochondrial DNA Synthetic aromatic-cationic tetrapeptide, not genome encoded
Length 24 amino acids cytoplasmic form, 21 amino acids mitochondrial form 16 amino acids 4 amino acids
Mechanism class Cytoprotective and anti-apoptotic signalling Metabolic and fuel-sensing signalling Inner membrane and cardiolipin interaction
Primary molecular targets described gp130-containing receptor complexes, Bax and related Bcl-2 family proteins Folate one-carbon cycle, AICAR and AMPK, nuclear stress-response factors Cardiolipin, cytochrome c interaction, cristae architecture
Common research models Neuronal cultures, retinal pigment epithelium, ischaemia and oxidative stress models Skeletal muscle, adipose tissue, diet-induced obesity and exercise models Cardiac and renal ischaemia-reperfusion, heart failure models, mitochondrial myopathy programmes
Endogenous in humans Yes, detectable in circulation Yes, detectable in circulation No
Clinical-stage programmes reported None established None established Yes, elamipretide has been evaluated in registered trials
Typical research framing Retrograde stress signal Exercise-mimetic metabolic signal Mitochondria-targeted bioenergetic compound

Two practical points follow from that table. First, humanin and MOTS-c are measurable in human samples, so they can serve both as intervention compounds and as biomarkers of mitochondrial state, while SS-31 can only be the former. Second, SS-31 is the only one of the three with a substantial registered clinical literature, which gives it a different evidence profile even though the laboratory mechanism work is younger in some respects than the humanin literature. Related catalog compounds are grouped under mitochondrial energy.

What do studies report on humanin and MOTS-c in metabolic models?

Both peptides have metabolic literatures, but they reach metabolism from different directions. The MOTS-c literature is metabolic at its foundation, while the humanin metabolic literature grew out of cytoprotection and aging work.

For MOTS-c, the anchor study remains the 2015 Cell Metabolism report, which described effects on insulin sensitivity and on body composition in rodents fed obesogenic diets, with the folate cycle and AMPK proposed as the mediating axis (PMID 25738459). Subsequent work in muscle biology extended the picture toward exercise. The 2021 Nature Communications study reported that skeletal muscle and plasma concentrations of the peptide respond to exercise and that measures of physical function in aged animals tracked with the peptide (PMID 33473109). Reviews in the field, including the 2017 Journal of Physiology overview of mitochondrially derived peptides as metabolic regulators, position MOTS-c within a wider set of signals that report mitochondrial status to metabolic tissues (PMID 28574175).

For humanin, the key metabolic reference is the 2009 PLoS One study describing humanin as a central regulator of peripheral insulin action in rodents, a finding that places at least part of its metabolic effect upstream of the tissues themselves (PMID 19623253). The 2016 Aging paper on naturally occurring mitochondrial-derived peptides reported that circulating concentrations of humanin and of humanin-like peptides relate to age and to markers of insulin sensitivity and inflammation, which is the main reason humanin appears in metabolic aging panels at all (PMID 27070352).

The honest summary is that MOTS-c has the stronger direct metabolic mechanism story and humanin has the broader association data across aging phenotypes. Neither body of work supports claims about outcomes in people, and the rodent models involved differ enough in diet, strain and endpoint that cross-study comparison should be made cautiously.

What does the literature report on humanin in neuronal, retinal and aging models?

Humanin's strongest experimental record is in models of cellular stress in post-mitotic tissue, particularly neurons and retinal pigment epithelium. This is where the peptide was first found and where its anti-apoptotic mechanism is most directly tested.

The 2001 Proceedings of the National Academy of Sciences discovery paper reported that humanin rescued neuronal cells from death induced by a range of familial Alzheimer's disease gene constructs and by amyloid beta exposure, which is the origin of the peptide's name and of the long-running interest in neurodegeneration models (PMID 11371646). It is important to read that result as what it is: a cell-culture rescue finding under defined insults, not evidence about clinical neurodegeneration.

In the eye, The mitochondrial-derived peptide humanin protects RPE cells from oxidative stress, senescence, and mitochondrial dysfunction, published in Investigative Ophthalmology and Visual Science in 2016, reported protective effects in retinal pigment epithelial cells exposed to oxidative challenge, along with changes in markers of senescence and mitochondrial function (PMID 26990160). Retinal pigment epithelium is a useful model here because it is long-lived, heavily oxidative and clinically relevant to age-related eye disease, so it sits at the intersection of humanin's two main research themes.

On the aging side, the 2016 Aging study on age-dependent mitochondrial-derived peptides reported declining circulating concentrations with age in the populations sampled and associations with apoptosis and inflammatory markers (PMID 27070352). Association is not causation, and the sampling in such studies is cross-sectional rather than longitudinal, which limits what can be inferred about trajectory in any individual. The useful conclusion for a laboratory is narrower and more durable: humanin behaves as a stress-responsive signal whose concentration carries information about mitochondrial state.

What does the literature report on SS-31 and elamipretide in cardiac and kidney models?

SS-31 has the most clinically advanced record of the three compounds, with published preclinical work concentrated in cardiac and renal ischaemia and a set of registered trials under the name elamipretide. Its reported mechanism is consistent across those settings: stabilising the interaction between cardiolipin and the inner membrane protein complexes so that electron transport stays coupled and peroxidase side reactions are limited.

The 2013 Journal of the American Society of Nephrology study reported that SS-31 interacts with cardiolipin and supports recovery of mitochondrial function after ischaemic stress in kidney models, with the cardiolipin interaction proposed as the direct cause rather than generic antioxidant action (PMID 23813215). The 2014 British Journal of Pharmacology account developed that argument into a broader framework, describing a first-in-class cardiolipin-protective compound intended to restore bioenergetics in tissues with high mitochondrial density (PMID 24117165).

In the clinical literature, Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide, published in Circulation: Heart Failure in 2017, reported a placebo-controlled evaluation in adults with heart failure with reduced ejection fraction, in which left ventricular volume measures were the main imaging endpoints and responses differed across the assigned trial amounts tested (PMID 29217757). The study was short and exploratory in scale, and it should be read as hypothesis-generating rather than as settled evidence of benefit. Later elamipretide programmes in primary mitochondrial myopathy and in specific genetic mitochondrial disorders have produced mixed results, and the compound has not become an established standard of care in any indication.

For a research buyer, the practical consequence is that SS-31 arrives with more human pharmacology context than humanin or MOTS-c, which changes what kind of comparison a laboratory can make, but it does not change the regulatory status of the material supplied. Catalog SS-31 is research-use-only.

Do humanin and MOTS-c change with age and exercise?

Research suggests both peptides are dynamic rather than static, and that is a large part of why they are studied as signals. The two respond to different stimuli, though, and the quality of evidence differs.

For humanin, the 2016 Aging study reported age-dependent differences in circulating concentrations of humanin and related humanin-like peptides, together with associations with apoptosis and inflammatory markers (PMID 27070352). The general reading in the field is that humanin tends to be lower in older samples, with variation by tissue and by assay method. Because immunoassays for humanin differ between groups and absolute values are not well standardised, cross-study comparison of concentrations is unreliable and within-study comparisons carry more weight.

For MOTS-c, the 2021 Nature Communications study is the main source, reporting that exercise raises the peptide in skeletal muscle and plasma and that older animals in the experiments showed age-related differences in physical function related to the peptide (PMID 33473109). That combination, an exercise-responsive mitochondrial peptide that also tracks with aging, is what gave MOTS-c its reputation as an exercise-mimetic candidate. The caveat is the same as for humanin: assay standardisation is immature, and the human sampling behind these claims is limited in size.

Both findings support the retrograde signalling model, in which mitochondrial state is reported outward through peptide messengers. They do not establish that raising either peptide externally reproduces the effects of exercise or reverses the effects of age, and the published work does not test that proposition in people.

Which peptide fits which research question?

Selection generally follows the mechanism class rather than the peptide's popularity. A model that stresses mitochondrial membranes and measures bioenergetic output points toward SS-31. A model that measures glucose flux, AMPK activation or muscle energetics points toward MOTS-c. A model that measures apoptosis, caspase activation, cytochrome c release or survival under an insult points toward humanin.

For apoptosis endpoints, humanin's advantage is that its reported target, Bax translocation, sits directly in the pathway being measured, so the mechanistic chain between compound and readout is short (PMID 12732850). Many groups use the HNG analogue instead of native humanin because the literature reports greater potency in these assays, and that substitution should be stated explicitly in methods because the two are not equivalent reagents.

For metabolic endpoints, MOTS-c has the better-developed pathway story, with the folate cycle and AMPK giving clear intermediate measurements that can confirm engagement rather than relying solely on downstream phenotype (PMID 25738459). Laboratories often pair MOTS-c exposure with phospho-AMPK blots and with metabolite panels covering one-carbon intermediates.

For membrane and bioenergetic endpoints, SS-31 is the natural comparator because its reported mechanism is physical and measurable: cardiolipin association, cristae morphology by electron microscopy, respiratory control ratios and reactive species production (PMID 23813215). It is also the only one of the three with human pharmacology data to contextualise preclinical findings (PMID 29217757).

When a study is designed to ask which mechanism matters most in a given tissue, including more than one of the three as separate arms is more informative than choosing a single compound, because the three act on different nodes of the same organelle.

Are humanin, MOTS-c and SS-31 ever studied together?

Direct head-to-head studies are uncommon, and most of what is written about the three together comes from review articles rather than from experiments that placed them in the same design. That is a genuine gap in the literature and worth stating plainly.

The mitochondrial-derived peptide reviews, including the 2017 Journal of Physiology overview, group humanin and MOTS-c together as members of one emerging class and discuss them in parallel, but they generally treat SS-31 separately because it is synthetic and its mechanism is biophysical rather than signalling (PMID 28574175). The 2016 Aging study on age-dependent mitochondrial-derived peptides did compare humanin with the small humanin-like peptides in the same samples, which is the closest common example of a within-family comparison (PMID 27070352).

Where combined designs would be most informative is in models with both bioenergetic failure and apoptotic loss, such as ischaemia-reperfusion in heart or kidney. In principle, a membrane-stabilising compound and an anti-apoptotic signal act at different points of the same injury cascade, so additivity is a reasonable hypothesis. It remains a hypothesis. Nothing in the published record establishes that combining these peptides produces effects beyond those of the individual compounds, and any laboratory running such a design should treat it as exploratory and power it accordingly.

For procurement, that means a comparative project typically draws from more than one catalog line. Compounds in this area are grouped on the Real Peptides mitochondrial energy collection, and the full catalog is available through the shop.

What are the limits of the current evidence?

The evidence limits are substantial and apply unevenly across the three compounds, so they are worth separating.

For humanin, most mechanistic work is in cell culture, often with the more potent HNG analogue rather than the native sequence, and often at concentrations chosen for assay convenience rather than for physiological relevance. The receptor model is incomplete, the relative contribution of the intracellular and extracellular routes is unresolved, and the presence of nuclear-encoded sequences resembling the mitochondrial reading frame complicates interpretation of where circulating peptide originates. Human data are observational and cross-sectional.

For MOTS-c, the main mechanistic study is rodent and the exercise work is a mixture of rodent experiments and limited human sampling (PMID 25738459, PMID 33473109). The folate cycle and AMPK axis is plausible and supported, but the nuclear translocation model is newer and less firmly established. Assay standardisation for measuring the peptide in biological samples is not mature, which affects every study that reports circulating concentrations.

For SS-31, the preclinical mechanism is relatively well supported, but the clinical record is mixed. The 2017 heart failure trial was small and exploratory, with imaging endpoints rather than clinical outcomes (PMID 29217757), and subsequent programmes in mitochondrial disease have not produced a uniformly positive picture. A compound with a convincing mechanism can still fail to translate, and elamipretide is a useful case study in that gap.

Across all three, the common limitation is that mitochondrial biology is highly tissue-specific. A result in retinal pigment epithelium does not transfer to cardiomyocytes, and a result in rodent skeletal muscle does not transfer to human skeletal muscle without direct testing. None of this literature supports claims of human benefit, and none of these compounds is approved for human use.

What should a laboratory verify before sourcing these peptides?

Verification before procurement comes down to identity, documentation and traceability, and it matters more for short peptides than researchers sometimes expect, because short sequences are easy to synthesise and easy to mislabel.

The first check is molecular identity. Each compound has a defined sequence and molecular weight, and a supplier should be able to confirm the CAS number and the molecular formula for the material being purchased. Confirming that the listed identity matches the sequence a study protocol calls for prevents the common error of ordering an analogue when the native peptide was intended, or the reverse. This applies with particular force to humanin, where native humanin and the HNG analogue appear in the literature under similar names but are distinct molecules with different reported potencies.

The second check is analytical documentation. Real Peptides publishes independent third-party certificates of analysis for every batch at /coas/, which allows a laboratory to match the lot in hand against its own documentation rather than relying on a general product claim. Matching the lot number on the container to the published certificate is the step that makes the documentation meaningful.

The third check is catalog clarity. MOTS-c and SS-31 each have their own compound pages describing the research context for that material, and the available presentations for MOTS-c include the lyophilised peptide and a liquid spray format. Supplier location and shipping information is published separately.

One point should be stated directly, because it comes up often. Real Peptides does not provide preparation or use guidance for any catalog compound, because these are research-use-only materials. The only quantitative framework appropriate to discuss is concentration, expressed as milligrams of peptide per millilitre of solvent, which is what determines how much compound is present in a given volume of a prepared stock. From that figure a laboratory calculates the micrograms of peptide delivered per assay in its own validated protocol. Nothing beyond that concentration framework is supplied, and no preparation steps, handling sequences or use instructions are offered.

All compounds discussed on this page are sold for laboratory research use only and are not for human consumption.

References

  • A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proceedings of the National Academy of Sciences. 2001. PMID: 11371646. pubmed.ncbi.nlm.nih.gov/11371646
  • Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature. 2003. PMID: 12732850. pubmed.ncbi.nlm.nih.gov/12732850
  • Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry. 2004. PMID: 15178689. pubmed.ncbi.nlm.nih.gov/15178689
  • Humanin: a novel central regulator of peripheral insulin action. PLoS One. 2009. PMID: 19623253. pubmed.ncbi.nlm.nih.gov/19623253
  • The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013. PMID: 23813215. pubmed.ncbi.nlm.nih.gov/23813215
  • First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014. PMID: 24117165. pubmed.ncbi.nlm.nih.gov/24117165
  • The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015. PMID: 25738459. pubmed.ncbi.nlm.nih.gov/25738459
  • The mitochondrial-derived peptide humanin protects RPE cells from oxidative stress, senescence, and mitochondrial dysfunction. Investigative Ophthalmology and Visual Science. 2016. PMID: 26990160. pubmed.ncbi.nlm.nih.gov/26990160
  • Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging. 2016. PMID: 27070352. pubmed.ncbi.nlm.nih.gov/27070352
  • Mitochondrially derived peptides as novel regulators of metabolism. The Journal of Physiology. 2017. PMID: 28574175. pubmed.ncbi.nlm.nih.gov/28574175
  • Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circulation: Heart Failure. 2017. PMID: 29217757. pubmed.ncbi.nlm.nih.gov/29217757
  • MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021. PMID: 33473109. pubmed.ncbi.nlm.nih.gov/33473109

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

Both are mitochondrial-derived peptides encoded inside mitochondrial DNA, so they share a family, but they come from different genes and act differently. Humanin is read from the 16S rRNA region and studied as a cytoprotective signal. MOTS-c is read from the 12S rRNA region and studied as a metabolic regulator.
No. SS-31, also called elamipretide, is a synthetic aromatic-cationic tetrapeptide designed to concentrate at the inner mitochondrial membrane and interact with cardiolipin. It is not encoded by any genome and is not endogenous. Humanin is a natural peptide written into mitochondrial DNA, so the two belong to different categories entirely.
SS-31 has the larger registered clinical record under the name elamipretide, including a placebo-controlled heart failure study published in Circulation: Heart Failure in 2017. Humanin human data are mostly observational, measuring circulating concentrations across age groups rather than testing the peptide as an intervention in controlled trials.
Yes, and reviews often discuss them together, but direct head-to-head experimental comparisons remain uncommon in the published literature. Because they act on different nodes of mitochondrial biology, including both as separate arms can be informative, though such designs should be treated as exploratory and powered accordingly.
HNG is humanin with the serine at position 14 replaced by glycine. The literature reports that this substitution makes the peptide considerably more potent in cytoprotection assays. The two are distinct molecules, so methods sections should state which was used, and procurement should confirm the exact sequence ordered.
No. Real Peptides supplies research-use-only compounds and does not provide preparation or use guidance of any kind. The only quantitative framework discussed is concentration, expressed as milligrams of peptide per millilitre of solvent, from which a laboratory calculates micrograms per assay within its own validated protocol.
Immunoassays for humanin and MOTS-c are not well standardised across research groups, so absolute concentration values differ substantially between publications. Within-study comparisons between groups carry more weight than cross-study comparisons of absolute numbers, and this limitation applies to most reported age and exercise associations.
Real Peptides publishes independent third-party certificates of analysis for every batch at /coas/. Matching the lot number printed on the container against the published certificate is the step that makes the documentation meaningful, alongside confirming the CAS number and molecular identity of the compound before procurement.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now